AREVA, NCI to develop radiopharmaceutical drug
AREVA, with support from AEC Partners, has signed a cooperative research and development agreement with the National Cancer Institute (NCI) to develop a new treatment to fight cancer.

As part of the agreement, the Bethesda, Md.-based AREVA said it will provide medical quality lead-212 to the NCI for the design of a new radiopharmaceutical drug.

Until recently, lead-212 was considered a scarce radioactive element, but is now figuring in promising research on treatment for certain cancers for which the current arsenal of therapies has only limited results, AREVA said.